Press release
Anemia In Chronic Kidney Disease Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Disc Medicine, 3SBio, Kind Pharmaceuticals, Jiangsu Hansoh Pharmaceuticals, Genexine
"Anemia In Chronic Kidney Disease Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Anemia In Chronic Kidney Disease Market.
The Anemia In Chronic Kidney Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Anemia In Chronic Kidney Disease Pipeline Report: https://www.delveinsight.com/sample-request/anemia-in-chronic-kidney-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Anemia In Chronic Kidney Disease treatment therapies with a considerable amount of success over the years.
• Anemia In Chronic Kidney Disease companies working in the treatment market are Jiangsu HengRui Medicine, Disc Medicine, 3SBio, Kind Pharmaceuticals, Jiangsu Hansoh Pharmaceuticals, Genexine, and others, are developing therapies for the Anemia In Chronic Kidney Disease treatment
• Emerging Anemia In Chronic Kidney Disease therapies in the different phases of clinical trials are- DDO-3055, DISC 0974, SSS 17, AND017, Pegol-Sihematide, Efepoetin alfa, and others are expected to have a significant impact on the Anemia In Chronic Kidney Disease market in the coming years.
• In April 2023, The Phase 3 clinical trial of GX-E4 (Efepoetin alfa), a potential treatment for anaemia brought on by chronic kidney disease, has revealed preliminary results, according to Genexine and its Asian regional partner, KG Bio. At the World Congress of Nephrology (WCN2023), its noninferiority results in comparison to Mircera (Methoxy Polyethylene Glycol-epoetin beta) were reported.
Anemia In Chronic Kidney Disease Overview
Anemia in Chronic Kidney Disease (CKD) is a common complication where the kidneys' ability to produce erythropoietin, a hormone that stimulates red blood cell production, is impaired. This condition leads to a reduction in the number of red blood cells and, consequently, a lower level of hemoglobin, which is essential for carrying oxygen throughout the body.
Get a Free Sample PDF Report to know more about Anemia In Chronic Kidney Disease Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/anemia-in-chronic-kidney-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Emerging Anemia In Chronic Kidney Disease Drugs Under Different Phases of Clinical Development Include:
• DDO-3055: Jiangsu HengRui Medicine
• DISC: 0974 Disc Medicine
• SSS 17: 3SBio
• AND017: Kind Pharmaceuticals
• Pegol-Sihematide: Jiangsu Hansoh Pharmaceuticals
• Efepoetin alfa: Genexine
Anemia In Chronic Kidney Disease Route of Administration
Anemia In Chronic Kidney Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
Anemia In Chronic Kidney Disease Molecule Type
Anemia In Chronic Kidney Disease Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
Anemia In Chronic Kidney Disease Pipeline Therapeutics Assessment
• Anemia In Chronic Kidney Disease Assessment by Product Type
• Anemia In Chronic Kidney Disease By Stage and Product Type
• Anemia In Chronic Kidney Disease Assessment by Route of Administration
• Anemia In Chronic Kidney Disease By Stage and Route of Administration
• Anemia In Chronic Kidney Disease Assessment by Molecule Type
• Anemia In Chronic Kidney Disease by Stage and Molecule Type
DelveInsight's Anemia In Chronic Kidney Disease Report covers around 10+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Further Anemia In Chronic Kidney Disease product details are provided in the report. Download the Anemia In Chronic Kidney Disease pipeline report to learn more about the emerging Anemia In Chronic Kidney Disease therapies
https://www.delveinsight.com/sample-request/anemia-in-chronic-kidney-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key companies in the Anemia In Chronic Kidney Disease Therapeutics Market include:
Key companies developing therapies for Anemia In Chronic Kidney Disease are - FibroGen Inc, FortuneRock (China) Ltd, General Biologics Inc, Genexine Inc, Great Bay Bio Holdings Ltd, GSK plc, 3SBio Inc, Akebia Therapeutics Inc, Avesthagen Ltd, Biocad, Chong Kun Dang Pharmaceutical Corporation, Dong-A Socio Holdings Co Ltd, Jiangsu Hengrui Medicine Co Ltd, Liminal BioSciences Inc, Panacea Biotec Ltd, Panion & Bf Biotech Inc, PharmaEssentia Corp, PhytoHealth Corp, Jiangsu Hansoh Pharmaceutical Group Co Ltd, UBI Pharma Inc, Uni-Bio Science Group Ltd, Xenetic Biosciences Inc, Zosano Pharma Corp, Shanghai Chemo Wanbang Biopharma Co Ltd, SunBio Inc, HEC Pharma Co Ltd, HK inno.N Corp, Imagine Pharma LLC, InSilico Medicine, Japan Tobacco Inc, Jecho Biopharmaceuticals Co Ltd, Zydus Lifesciences Ltd, and others.
Anemia In Chronic Kidney Disease Pipeline Analysis:
The Anemia In Chronic Kidney Disease pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Anemia In Chronic Kidney Disease with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Anemia In Chronic Kidney Disease Treatment.
• Anemia In Chronic Kidney Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Anemia In Chronic Kidney Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Anemia In Chronic Kidney Disease market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Anemia In Chronic Kidney Disease drugs and therapies
https://www.delveinsight.com/sample-request/anemia-in-chronic-kidney-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Anemia In Chronic Kidney Disease Pipeline Market Drivers
• Increase in the geriatric population with a higher risk of renal anemia due to age-related renal issues, increase in research and developmental activities are some of the important factors that are fueling the Anemia In Chronic Kidney Disease Market.
Anemia In Chronic Kidney Disease Pipeline Market Barriers
• However, high-cost associated with the disease, side effects associated with the disease and other factors are creating obstacles in the Anemia In Chronic Kidney Disease Market growth.
Scope of Anemia In Chronic Kidney Disease Pipeline Drug Insight
• Coverage: Global
• Key Anemia In Chronic Kidney Disease Companies: Jiangsu HengRui Medicine, Disc Medicine, 3SBio, Kind Pharmaceuticals, Jiangsu Hansoh Pharmaceuticals, Genexine, and others
• Key Anemia In Chronic Kidney Disease Therapies: DDO-3055, DISC 0974, SSS 17, AND017, Pegol-Sihematide, Efepoetin alfa, and others
• Anemia In Chronic Kidney Disease Therapeutic Assessment: Anemia In Chronic Kidney Disease current marketed and Anemia In Chronic Kidney Disease emerging therapies
• Anemia In Chronic Kidney Disease Market Dynamics: Anemia In Chronic Kidney Disease market drivers and Anemia In Chronic Kidney Disease market barriers
Request for Sample PDF Report for Anemia In Chronic Kidney Disease Pipeline Assessment and clinical trials
https://www.delveinsight.com/sample-request/anemia-in-chronic-kidney-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Table of Contents
1. Anemia In Chronic Kidney Disease Report Introduction
2. Anemia In Chronic Kidney Disease Executive Summary
3. Anemia In Chronic Kidney Disease Overview
4. Anemia In Chronic Kidney Disease- Analytical Perspective In-depth Commercial Assessment
5. Anemia In Chronic Kidney Disease Pipeline Therapeutics
6. Anemia In Chronic Kidney Disease Late Stage Products (Phase II/III)
7. Anemia In Chronic Kidney Disease Mid Stage Products (Phase II)
8. Anemia In Chronic Kidney Disease Early Stage Products (Phase I)
9. Anemia In Chronic Kidney Disease Preclinical Stage Products
10. Anemia In Chronic Kidney Disease Therapeutics Assessment
11. Anemia In Chronic Kidney Disease Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Anemia In Chronic Kidney Disease Key Companies
14. Anemia In Chronic Kidney Disease Key Products
15. Anemia In Chronic Kidney Disease Unmet Needs
16 . Anemia In Chronic Kidney Disease Market Drivers and Barriers
17. Anemia In Chronic Kidney Disease Future Perspectives and Conclusion
18. Anemia In Chronic Kidney Disease Analyst Views
19. Appendix
20. About DelveInsight
Related Reports:
Anemia In Chronic Kidney Disease Market https://www.delveinsight.com/report-store/anemia-in-chronic-kidney-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Anemia In Chronic Kidney Disease Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),
Anemia In Chronic Kidney Disease Epidemiology https://www.delveinsight.com/report-store/anemia-in-chronic-kidney-disease-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Anemia In Chronic Kidney Disease Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports:
Herpes Simplex Virus Market
https://www.delveinsight.com/report-store/herpes-simplex-market
DelveInsight's "Herpes Simplex - Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the Herpes Simplex, historical and forecasted epidemiology as well as the Herpes Simplex market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
Hypercoagulability Market
https://www.delveinsight.com/report-store/hypercoagulability-market
DelveInsight's "Hypercoagulability- Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Hypercoagulability, historical and forecasted epidemiology as well as the Hypercoagulability market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Idiopathic Thrombocytopenic Purpura Market
https://www.delveinsight.com/report-store/idiopathic-thrombocytopenic-purpura-market
DelveInsight's "Idiopathic Thrombocytopenic Purpura Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Idiopathic Thrombocytopenic Purpura, historical and forecasted epidemiology as well as the Idiopathic Thrombocytopenic Purpura market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Inguinal Hernia Market
https://www.delveinsight.com/report-store/inguinal-hernia-market
DelveInsight's "Inguinal Hernia Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Inguinal Hernia, historical and forecasted epidemiology as well as the Inguinal Hernia market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Charcot-marie-tooth Disease Market
https://www.delveinsight.com/report-store/charcot-marie-tooth-disease-market
DelveInsight's 'Charcot-Marie-Tooth Disease Market Insights, Epidemiology, and Market Forecast 2032' report deliver an in-depth understanding of the Charcot-Marie-Tooth Disease, historical and forecasted epidemiology as well as the Charcot-Marie-Tooth Disease market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan
Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Anemia In Chronic Kidney Disease Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Disc Medicine, 3SBio, Kind Pharmaceuticals, Jiangsu Hansoh Pharmaceuticals, Genexine here
News-ID: 3589065 • Views: …
More Releases from DelveInsight Business Research
Pharma Asset Management Success Story: Strategic In-Licensing in the Atrial Fibr …
DelveInsight, a leading business consulting and market research firm, is pleased to announce the successful completion of an Asset Prioritization project that enabled a mid-sized pharmaceutical client to identify, evaluate, and secure a high-value therapeutic asset for in-licensing in the Atrial Fibrillation (AF) space. The case study highlights how evidence-based insights, structured methodologies, and multi-layered evaluations supported the client in achieving its long-term strategic growth goals.
Objective of the Case Study
The…
Myopia Clinical Trials Outlook 2025: Competitive Landscape, Regulatory Milestone …
(Albany, USA) - DelveInsight's newly released report, "Myopia Pipeline Insight 2025," delivers an in-depth assessment of the clinical trial landscape, regulatory progress, and therapeutic development trends shaping the Myopia therapeutics market. The analysis highlights ongoing clinical advancements, pipeline opportunities, and the potential impact of emerging therapies on patient care and market dynamics.
According to DelveInsight's evaluation, the Myopia pipeline remains highly active, with 8+ pharmaceutical and biotechnology companies investigating more than…
Global Biopsy Devices Market to Reach USD 10.81 Billion by 2032, Driven by Risin …
The global biopsy devices market is poised for significant growth, with market size projected to increase from USD 5,813.16 million in 2024 to USD 10,812.77 million by 2032, expanding at a CAGR of 8.09% during 2025-2032. The robust expansion is being driven by the growing incidence of cancers, rising demand for minimally invasive diagnostic procedures, and rapid advancements in biopsy technologies.
Biopsy devices play a crucial role in disease diagnosis by…
Global General Surgery Devices Market to Reach USD 35.4 Billion by 2032, Driven …
According to the latest market analysis, the global general surgery devices market is set for robust growth, increasing from USD 21,786.29 million in 2024 to USD 35,399.63 million by 2032, expanding at a CAGR of 6.34% during 2025-2032. This growth reflects a surge in surgical procedures, continuous technological advancements, and rising demand for minimally invasive and robotic-assisted surgical techniques across healthcare systems worldwide.
DelveInsight's General Surgery Devices Market Report 2032 provides…
More Releases for Disease
Protheragen Announces Disease Model Development Services to Enhance Rare Disease …
Protheragen announced the release of its disease model development services provided to enhance rare disease research. With an increasing focus on rare diseases and the need for tailored research models, Protheragen is dedicated to providing cutting-edge solutions to support this important area of medical research.
Rare diseases, which affect a small percentage of the population, pose unique challenges for researchers due to their limited understanding and lack of available treatment options.…
Biopharmaceutical Fermentation Market 2022 | Growing Morbidity of Genetic Diseas …
According to Precision Business Insights (PBI), the latest report, the biopharmaceutical fermentation market is expected to be valued at USD 10,302.1 million in 2022, growing at a 4.7% CAGR from 2022 to 2028. The growing prevalence of chronic illness, cancer, cardiac diseases, infectious diseases, antibiotic resistance, autoimmune diseases, etc., globally causes the leaning toward biopharmaceutical products, which show promising results in the research studies. Moreover, new findings by the…
Global Inflammatory Bowel Disease (IBD) Market Key Players Analysis, Disease Ind …
Global Inflammatory Bowel Disease (IBD) Market, valued at USD 210.5 Billion in the year 2020 has been driven by factors such as the increasing prevalence of Ulcerative Colitis and Crohn’s Disease, advances in medical technology, government support for inflammatory bowel disease treatment research, and the ubiquity of anxiety and depression. Moreover, factors such as the irregular food habits, unhealthy lifestyle of people, increased level of pollution and increase in alcohol…
Moyamoya Disease Market - A Scientometric Assessment of Disease During 2018-23
Market Highlight:
Moyamoya disease (MMD) is a chronic, cerebrovascular disease characterized by progressive stenosis in the internal carotid artery and an abnormal vascular network at the base of the brain. The stroke is one of the significant symptoms of moyamoya disease, which further leads to paralysis of the face, arms, and legs, loss of speech, and temporary loss of neurologic function of body parts, visual disturbances, headaches, developmental delay, and…
Refsum Disease Industry An Overview of A New Disease - 2018
"Refsum Disease" is a genetic disorder which is inherited as an autosomal recessive trait. The condition is characterized by progressive loss of vision (retinitis pigmentosa), failure of muscle coordination (ataxia), degenerative nerve disease (peripheral neuropathy), and dry, rough, scaly skin (ichthyosis). The accumulation of fatty acid (phytanic acid) in blood plasma and tissues is the main cause of refsum disease. This occurs due to malfunction of the enzyme producing gene…
Chagas Disease (Infectious Disease) Pipeline Forecast Report, H1, 2017 [MRH]
Market Research Hub's Pharmaceutical and Healthcare latest pipeline guide Chagas Disease - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Chagas Disease Market (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and…
